A Phase 2, Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients Evaluating a Predetermined Biomarker Signature
Phase of Trial: Phase II
Latest Information Update: 26 Aug 2018
Price : $35 *
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Mar 2018 Status changed from not yet recruiting to recruiting.
- 08 Feb 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.